Other names: Remicade
Categories: Prescription Medication
Description:
Infliximab (Remicade) is a biologic DMARD that targets tumor necrosis factor-alpha (TNF-α), helping to reduce joint inflammation and prevent long-term damage in rheumatoid arthritis. Unlike adalimumab or etanercept, infliximab is given by intravenous infusion in a clinic or infusion center, typically at weeks 0, 2, and 6, then every 8 weeks. It is often used in moderate to severe RA and is most effective when combined with methotrexate, which reduces the risk of the body forming antibodies against the drug. Side effects include infusion reactions (fever, rash, shortness of breath), higher risk of infections (TB, hepatitis, fungal infections), and rarely heart failure or demyelinating disease. While very effective, its IV administration and monitoring needs can be less convenient compared to self-injectable TNF inhibitors.
Treatment For:
AI generated Summary: Based on the provided information, there are no user reviews available for the treatment "Infliximab" against the disease "Rheumatoid Arthritis". Without any reviews or ratings, it is not possible to determine the effectiveness of this treatment for the given disease. More data and user experiences are needed to provide a meaningful summary of the treatment's efficacy.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
